Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer

(2016) E. Van Cutsem et al.   ANNALS OF ONCOLOGY

Impact of tumour RAS/BRAF status in a first-line study of panitumumab + FOLFIRI in patients with metastatic colorectal cancer

(2016) Meinolf Karthaus et al.   BRITISH JOURNAL OF CANCER

Adjuvant Oral Uracil-Tegafur with Leucovorin for Colorectal Cancer Liver Metastases: A Randomized Controlled Trial

(2016) Kiyoshi Hasegawa et al.   PLoS One

Ninety-day Postoperative Mortality Is a Legitimate Measure of Hepatopancreatobiliary Surgical Quality

(2015) Yoshihiro Mise et al.   ANNALS OF SURGERY

The use of neo-adjuvant chemotherapy in patients with resectable colorectal liver metastases: Clinical risk score as possible discriminator

(2015) N. Ayez et al.   EJSO

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Treatment andRASMutations in Colorectal Cancer

(2015) Eric Van Cutsem et al.   JOURNAL OF CLINICAL ONCOLOGY

Role of neoadjuvant chemotherapy in resectable synchronous colorectal liver metastasis; An international multi-center data analysis using LiverMetSurvey

(2015) Glenn K. Bonney et al.   JOURNAL OF SURGICAL ONCOLOGY

Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX/cetuximab or FOLFIRI/cetuximab in a multidisciplinary concept (CELIM study)†

(2014) G. Folprecht et al.   ANNALS OF ONCOLOGY

RAS Mutations Predict Radiologic and Pathologic Response in Patients Treated with Chemotherapy Before Resection of Colorectal Liver Metastases

(2014) Yoshihiro Mise et al.   ANNALS OF SURGICAL ONCOLOGY

Discrepancy Between Recurrence-Free Survival and Overall Survival in Patients with Resectable Colorectal Liver Metastases: A Potential Surrogate Endpoint for Time to Surgical Failure

(2014) Masaru Oba et al.   ANNALS OF SURGICAL ONCOLOGY

Systematic review of outcomes of patients undergoing resection for colorectal liver metastases in the setting of extra hepatic disease

(2014) Michael Hwang et al.   EUROPEAN JOURNAL OF CANCER

Effect of Neoadjuvant Chemotherapy in Patients with Resectable Colorectal Liver Metastases

(2014) Dexiang Zhu et al.   PLoS One

Comparison Between Perioperative and Postoperative Chemotherapy After Potentially Curative Hepatic Resection for Metastatic Colorectal Cancer

(2013) Raphael Araujo et al.   ANNALS OF SURGICAL ONCOLOGY

Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial

(2013) Bernard Nordlinger et al.   LANCET ONCOLOGY

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Progression while Receiving Preoperative Chemotherapy Should Not Be an Absolute Contraindication to Liver Resection for Colorectal Metastases

(2012) Luca Viganò et al.   ANNALS OF SURGICAL ONCOLOGY

Comparison of oncological outcomes between neoadjuvant and adjuvant chemotherapy combined with surgery for resectable synchronous colorectal liver metastases

(2012) Seung Yeop Oh et al.   JOURNAL OF SURGICAL RESEARCH

Peri-operative chemotherapy for resectable colorectal liver metastasis: Does timing of systemic therapy matter?

(2011) Hugo Pinto Marques et al.   JOURNAL OF SURGICAL ONCOLOGY

Safety of hepatic resection for colorectal metastases in the era of neo-adjuvant chemotherapy

(2011) Alessandro Cucchetti et al.   LANGENBECKS ARCHIVES OF SURGERY

Is Perioperative Chemotherapy Useful for Solitary, Metachronous, Colorectal Liver Metastases?

(2010) Rene Adam et al.   ANNALS OF SURGERY

Patients With Initially Unresectable Colorectal Liver Metastases: Is There a Possibility of Cure?

(2009) René Adam et al.   JOURNAL OF CLINICAL ONCOLOGY

Is There a Survival Benefit to Neoadjuvant Versus Adjuvant Chemotherapy, Combined with Surgery for Resectable Colorectal Liver Metastases?

(2009) Nir Lubezky et al.   WORLD JOURNAL OF SURGERY

Impact of Preoperative Bevacizumab on Complications After Resection of Colorectal Liver Metastases: Case-Matched Control Study

(2009) Mahfud Mahfud et al.   WORLD JOURNAL OF SURGERY

Preoperative Chemotherapy Does Not Increase Morbidity or Mortality of Hepatic Resection for Colorectal Cancer Metastases

(2008) Charles R. Scoggins et al.   ANNALS OF SURGICAL ONCOLOGY

Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial

(2008) Bernard Nordlinger et al.   LANCET

Addition of Bevacizumab to Irinotecan- and Oxaliplatin-Based Preoperative Chemotherapy Regimens Does Not Increase Morbidity after Resection of Colorectal Liver Metastases

(2007) Srinevas K. Reddy et al.   JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS